[go: up one dir, main page]

CN115003818A - 病毒载体转导细胞的方法 - Google Patents

病毒载体转导细胞的方法 Download PDF

Info

Publication number
CN115003818A
CN115003818A CN202180010727.6A CN202180010727A CN115003818A CN 115003818 A CN115003818 A CN 115003818A CN 202180010727 A CN202180010727 A CN 202180010727A CN 115003818 A CN115003818 A CN 115003818A
Authority
CN
China
Prior art keywords
transduced
hours
cells
cell
incubation time
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180010727.6A
Other languages
English (en)
Inventor
王华茂
高慧萍
童潇
姚晔风
朱寅玉
李宗海
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kaixing Life Technology Shanghai Co ltd
Original Assignee
Keji Biomedical Shanghai Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN202110076311.6A external-priority patent/CN114854790A/zh
Application filed by Keji Biomedical Shanghai Co ltd filed Critical Keji Biomedical Shanghai Co ltd
Publication of CN115003818A publication Critical patent/CN115003818A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4215—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4261—Proteoglycans, e.g. glypican, brevican or CSPG4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

提供了病毒载体转导细胞的方法，还提供了用重组或异源基因转导的所获得细胞及其组合物，以及将其用于过继免疫疗法的方法。在不影响重组核酸的表达的前提下，该方法缩短了基因工程化细胞的制备过程中活化、转导的时间。

Description

PCT国内申请，说明书已公开。

Claims (37)

  1. PCT国内申请，权利要求书已公开。
CN202180010727.6A 2020-01-22 2021-01-22 病毒载体转导细胞的方法 Pending CN115003818A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN202010075423 2020-01-22
CN2020100754235 2020-01-22
CN202110076311.6A CN114854790A (zh) 2021-01-20 2021-01-20 病毒载体转导细胞的方法
CN2021100763116 2021-01-20
PCT/CN2021/073418 WO2021148019A1 (zh) 2020-01-22 2021-01-22 病毒载体转导细胞的方法

Publications (1)

Publication Number Publication Date
CN115003818A true CN115003818A (zh) 2022-09-02

Family

ID=76992048

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180010727.6A Pending CN115003818A (zh) 2020-01-22 2021-01-22 病毒载体转导细胞的方法

Country Status (4)

Country Link
US (1) US20240182920A1 (zh)
CN (1) CN115003818A (zh)
TW (1) TW202140790A (zh)
WO (1) WO2021148019A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117343927A (zh) * 2023-12-06 2024-01-05 上海药明巨诺生物医药研发有限公司 一种工程化细胞的核酸提取方法

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024527180A (ja) 2021-04-08 2024-07-22 クレージュ メディカル カンパニー，リミテッド 細胞免疫療法の使用

Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1531596A (zh) * 2000-08-31 2004-09-22 VIRxSYS�ɷ����޹�˾ 用病毒载体稳定转导细胞的方法
WO2016179283A1 (en) * 2015-05-05 2016-11-10 Fate Therapeutics, Inc. Modulation of t lymphocytes
WO2017068421A1 (en) * 2015-10-22 2017-04-27 Juno Therapeutics Gmbh Methods for culturing cells and kits and apparatus for same
CN107109438A (zh) * 2014-11-05 2017-08-29 朱诺治疗学股份有限公司 用于转导及细胞处理的方法
WO2018067992A1 (en) * 2016-10-07 2018-04-12 Novartis Ag Chimeric antigen receptors for the treatment of cancer
CA3061945A1 (en) * 2017-05-01 2018-11-08 Juno Therapeutics, Inc. Combination of a cell therapy and an immunomodulatory compound
WO2019032927A1 (en) * 2017-08-09 2019-02-14 Juno Therapeutics, Inc. METHODS FOR PRODUCING GENETICALLY MODIFIED CELL COMPOSITIONS AND COMPOSITIONS THEREOF
CN109762843A (zh) * 2018-12-29 2019-05-17 武汉波睿达生物科技有限公司 一种利用脐血来源的cd3阳性t细胞制备通用car-t细胞的方法
CN109804089A (zh) * 2016-07-29 2019-05-24 朱诺治疗学股份有限公司 用于评估复制型病毒存在或不存在的方法
CN109843915A (zh) * 2016-05-06 2019-06-04 朱诺治疗学股份有限公司 基因工程化细胞及其制备方法
WO2019113556A1 (en) * 2017-12-08 2019-06-13 Juno Therapeutics, Inc. Serum-free media formulation for culturing cells and methods of use thereof
WO2019157298A1 (en) * 2018-02-09 2019-08-15 Immatics US, Inc. Methods for manufacturing t cells
WO2019156926A1 (en) * 2018-02-06 2019-08-15 Seattle Children's Hospital (dba Seattle Children's Research Institute) Closed-system manufacturing process for car-t cells
CN110234756A (zh) * 2017-01-18 2019-09-13 F1肿瘤医学公司 转导和扩增免疫细胞的方法及其用途
CN110249046A (zh) * 2016-12-05 2019-09-17 朱诺治疗学股份有限公司 用于过继细胞疗法的工程化细胞的产生
CN110582287A (zh) * 2017-02-27 2019-12-17 朱诺治疗学股份有限公司 与在细胞疗法中给药有关的组合物、制品和方法

Patent Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1531596A (zh) * 2000-08-31 2004-09-22 VIRxSYS�ɷ����޹�˾ 用病毒载体稳定转导细胞的方法
CN107109438A (zh) * 2014-11-05 2017-08-29 朱诺治疗学股份有限公司 用于转导及细胞处理的方法
WO2016179283A1 (en) * 2015-05-05 2016-11-10 Fate Therapeutics, Inc. Modulation of t lymphocytes
WO2017068421A1 (en) * 2015-10-22 2017-04-27 Juno Therapeutics Gmbh Methods for culturing cells and kits and apparatus for same
CN109843915A (zh) * 2016-05-06 2019-06-04 朱诺治疗学股份有限公司 基因工程化细胞及其制备方法
CN109804089A (zh) * 2016-07-29 2019-05-24 朱诺治疗学股份有限公司 用于评估复制型病毒存在或不存在的方法
WO2018067992A1 (en) * 2016-10-07 2018-04-12 Novartis Ag Chimeric antigen receptors for the treatment of cancer
CN110249046A (zh) * 2016-12-05 2019-09-17 朱诺治疗学股份有限公司 用于过继细胞疗法的工程化细胞的产生
CN110234756A (zh) * 2017-01-18 2019-09-13 F1肿瘤医学公司 转导和扩增免疫细胞的方法及其用途
CN110582287A (zh) * 2017-02-27 2019-12-17 朱诺治疗学股份有限公司 与在细胞疗法中给药有关的组合物、制品和方法
CA3061945A1 (en) * 2017-05-01 2018-11-08 Juno Therapeutics, Inc. Combination of a cell therapy and an immunomodulatory compound
WO2019032927A1 (en) * 2017-08-09 2019-02-14 Juno Therapeutics, Inc. METHODS FOR PRODUCING GENETICALLY MODIFIED CELL COMPOSITIONS AND COMPOSITIONS THEREOF
WO2019113556A1 (en) * 2017-12-08 2019-06-13 Juno Therapeutics, Inc. Serum-free media formulation for culturing cells and methods of use thereof
WO2019156926A1 (en) * 2018-02-06 2019-08-15 Seattle Children's Hospital (dba Seattle Children's Research Institute) Closed-system manufacturing process for car-t cells
WO2019157298A1 (en) * 2018-02-09 2019-08-15 Immatics US, Inc. Methods for manufacturing t cells
CN109762843A (zh) * 2018-12-29 2019-05-17 武汉波睿达生物科技有限公司 一种利用脐血来源的cd3阳性t细胞制备通用car-t细胞的方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
E COSTELLO等: "Gene transfer into stimulated and unstimulated T lymphocytes by HIV-1-derived lentiviral vectors", 《GENE THER》, vol. 7, no. 7, pages 596 - 604 *
SABA GHASSEMI等: "Reducing Ex Vivo Culture Improves the Antileukemic Activity of Chimeric Antigen Receptor (CAR) T Cells", 《CANCER IMMUNOL RES》, vol. 6, no. 9, pages 1100 - 1109, XP055681222, DOI: 10.1158/2326-6066.CIR-17-0405 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117343927A (zh) * 2023-12-06 2024-01-05 上海药明巨诺生物医药研发有限公司 一种工程化细胞的核酸提取方法
CN117343927B (zh) * 2023-12-06 2024-03-12 上海药明巨诺生物医药研发有限公司 一种工程化细胞的核酸提取方法

Also Published As

Publication number Publication date
WO2021148019A1 (zh) 2021-07-29
TW202140790A (zh) 2021-11-01
US20240182920A1 (en) 2024-06-06

Similar Documents

Publication Publication Date Title
US11903967B2 (en) Method of preparing T cells with increased activity
Greco et al. Improving the safety of cell therapy with the TK-suicide gene
Zanetti Tapping CD4 T cells for cancer immunotherapy: the choice of personalized genomics
JP2025072432A (ja) Ｔｃｒ及びペプチド
JP2022507830A (ja) 治療薬を発現する改変細胞とその使用
US11458168B2 (en) NKT-cell subset for in vivo persistence and therapeutic activity and propagation of same
US12486327B2 (en) CAR for use in the treatment of HvG disease
JP2019531704A (ja) 免疫調節ポリペプチドならびに関連する組成物および方法
JP2020530294A5 (zh)
US20240287456A1 (en) A method for producing antigen-specific t cells
WO2019096115A1 (zh) 分离的t细胞受体、其修饰的细胞、编码核酸、表达载体、制备方法、药物组合物和应用
Pierini et al. Ovarian granulosa cell tumor characterization identifies FOXL2 as an immunotherapeutic target
CN115003818A (zh) 病毒载体转导细胞的方法
Tarannum et al. Engineering innate immune cells for cancer immunotherapy
US11739136B2 (en) Inducible dominant negative PD-1 and uses in adoptive cell therapy
Hillerdal et al. Avidity characterization of genetically engineered T-cells with novel and established approaches
Mason et al. RNA-loaded CD40-activated B cells stimulate antigen-specific T-cell responses in dogs with spontaneous lymphoma
WO2020042648A1 (zh) 改进的慢病毒载体
CN112251452A (zh) Til/tcr-t细胞治疗平台
JP2022513584A (ja) サイトカインを分泌するように改変されたｐｄｃ株
US20250345427A1 (en) Method
WO2025017308A1 (en) Anti-tcrb1 and anti-tcrb2 t cells
WO2024134206A2 (en) Chimeric antigen receptor
TR2021017264A2 (tr) Mr1t hücreleri̇ni̇n tetramer bağimsiz kolay i̇zolasyonu ve transgeni̇k car-mr1t-egfrt hücre üreti̇mi̇ i̇çi̇n bi̇r yöntem
WO2024015734A1 (en) Recombinant cytokine receptors and methods of use

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20250626

Address after: Room 303, 3 / F, 203 Fute North Road, China (Shanghai) pilot Free Trade Zone, Pudong New Area, Shanghai 200131

Applicant after: Kaixing Life Technology (Shanghai) Co.,Ltd.

Country or region after: China

Address before: 200231 building 12, 388 Yindu Road, Xuhui District, Shanghai

Applicant before: Keji biomedical (Shanghai) Co.,Ltd.

Country or region before: China

TA01 Transfer of patent application right